Similarly, trials are exploring monoclonal antibodies against IL-23, including ustekinumab (Chimenti et al., 2015), briakinumab, and tildrakizumab, which are currently used in the treatment of other autoimmune diseases (Markham, 2018; Verstockt et al., 2023). The gene discussed is IL23A; the disease is autoimmune disease.